A Mostly Green Session Still Left a Trail of Sharp Individual Losers
Even as a tame CPI print lifted the broader market and sent AI infrastructure names soaring, a distinct group of stocks moved in the opposite direction today — earnings misses, drug safety concerns, and analyst downgrades each punished individual names regardless of the constructive macro backdrop. Here are today’s top stock losers, ranked by percentage decline.
1. National CineMedia (NCMI) — Down 31% Despite a $275M Acquisition Announcement
Fundamental Data:
| Metric | Value |
|---|---|
| Today’s Move | -31% |
| Q2 2026 EPS | -$0.10 (missed -$0.09 estimate) |
| Q2 2026 Revenue | $58.4 million (missed $59.52M estimate) |
| Acquisition | Captivate Holdings, LLC — $275M enterprise value |
What Happened: National CineMedia shares fell sharply despite the company entering a definitive agreement to acquire Captivate Holdings, an operator of digital video elevator and lobby advertising across North America, at a $275 million enterprise value. The market’s reaction focused squarely on the underlying Q2 earnings and revenue miss rather than the acquisition news.
Why It Matters / What to Watch Tomorrow: A 31% drop on a quarter that missed by just a penny per share and roughly $1 million in revenue suggests the market’s real concern is the Captivate acquisition’s financing terms and integration risk, not the modest operational miss itself. Watch for details on how the deal will be funded and any dilution implications in coming sessions.
2. Neurocrine Biosciences (NBIX) — Falls Up to 5.8% on Drug Safety Concerns
Fundamental Data:
| Metric | Value |
|---|---|
| Today’s Move | -2% to -5.8% |
| Drug in Question | Vykat XR (acquired from Soleno in $2.9B deal, May 2026) |
| FDA AEMS Reports | 7 deaths linked to patients taking the drug (as of July 31, 2026) |
What Happened: Experts specializing in Prader-Willi Syndrome raised safety concerns over Vykat XR, the rare-disease drug Neurocrine acquired from Soleno for $2.9 billion just three months ago. The FDA’s Adverse Event Monitoring System showed seven reports of death linked to patients taking the drug through July 31.
Why It Matters / What to Watch Tomorrow: Drug safety signals represent the most severe binary risk category in biotech and pharma investing, and this development lands just months after a substantial $2.9 billion acquisition, raising immediate questions about that deal’s underlying due diligence. Watch closely for any formal FDA response, label update, or safety communication in the coming days.
3. Oklo Inc (OKLO) — Falls 4% Even After a Positive “Criticality” Milestone
Fundamental Data:
| Metric | Value |
|---|---|
| Today’s Move | -4.00% |
| Positive News | “Criticality” milestone achieved |
What Happened: Oklo shares declined even as the nuclear technology company announced it had reached a “criticality” milestone — a significant technical achievement in reactor development. The disconnect between positive operational news and a negative stock reaction highlights just how skeptically the market is currently pricing pre-revenue nuclear names.
Why It Matters / What to Watch Tomorrow: A stock falling on genuinely good news is a notable signal — it suggests investors are more focused on cash burn, dilution risk, or broader nuclear-sector sentiment than on individual technical milestones right now. Watch whether this proves to be a “sell the news” blip or the start of a deeper reassessment of Oklo’s valuation relative to its still pre-revenue status.
4. Performance Food Group (PFGC) — Slips 5% on Guidance Miss
Fundamental Data:
| Metric | Value |
|---|---|
| Today’s Move | -5% |
| Q4 Adjusted EPS | $1.59 (vs. $1.60 estimate) |
| Q4 Revenue | $18 billion (+6.4% YoY, vs. $18.09B estimate) |
| Q1 Guidance | $17.9B-$18.1B revenue (below $18.13B consensus) |
| FY27 Guidance | $72.5B-$73B revenue (below $72.68B consensus) |
What Happened: Performance Food Group’s Q4 results came in just below consensus on both EPS and revenue, and forward guidance for both Q1 and full fiscal year 2027 landed below Wall Street’s expectations, driving the stock lower despite still-positive year-over-year growth.
Why It Matters / What to Watch Tomorrow: The magnitude of the miss here is small in absolute terms, but the pattern of guidance coming in below consensus across multiple forward periods suggests genuine margin or volume pressure building in the foodservice distribution business. Watch for management commentary on input cost trends and customer demand in the food distribution channel.
5. Novo Nordisk (NVO) — Falls 3.4% on a Berenberg Downgrade
Fundamental Data:
| Metric | Value |
|---|---|
| Today’s Move | -3.4% |
| Catalyst | Berenberg downgrade |
| Competitive Pressure | Eli Lilly’s obesity drug dominance cited |
What Happened: Berenberg downgraded Novo Nordisk, specifically citing Eli Lilly’s growing dominance in the obesity drug market as a structural limit on Novo’s upside potential going forward.
Why It Matters / What to Watch Tomorrow: This downgrade reflects a broader sector rotation signal — competitive share shifts in the GLP-1/obesity drug category are reshaping how analysts value the two dominant players relative to one another. Watch for Novo’s response, including any pipeline updates or pricing strategy adjustments aimed at defending market share.
6. The Trade Desk (TTD) — Continues to Languish Near 5-Year Lows
Fundamental Data:
| Metric | Value |
|---|---|
| Today’s Move | -0.52% |
| Context | Trading just above a fresh multi-year low reached in prior sessions |
What Happened: The Trade Desk’s modest decline today extends a difficult multi-week stretch for the stock, which crashed to fresh multi-year lows after a Q2 earnings miss and weak Q3 guidance disappointed investors already concerned about slowing digital ad growth and rising competition from Amazon’s demand-side platform.
Why It Matters / What to Watch Tomorrow: With the stock hovering just above its 52-week low with no clear positive catalyst in sight, today’s small additional decline signals continued lack of buying conviction. Watch for any signs of stabilization or a reversal in the stock’s persistent downtrend over the next several sessions.
7. HubSpot (HUBS) — Part of a Broader Software Sector Pullback
Fundamental Data:
| Metric | Value |
|---|---|
| Sector Context | Software names broadly pulling back alongside SAP (-2%) |
| Peers Affected | CRM, MNDY, NOW, TEAM, TWLO, WDAY also declined |
What Happened: HubSpot declined alongside a broad pullback in recently strong software stocks, a group-wide rotation as investors took profits in enterprise software names that had rallied significantly in recent weeks.
Why It Matters / What to Watch Tomorrow: A sector-wide pullback across nearly a dozen well-known software names on the same day suggests broad profit-taking rather than any company-specific concern. Watch whether this proves to be a single-session rotation or the start of a more sustained shift away from high-multiple software names.
8. monday.com (MNDY) — Software Sector Weakness Extends
Fundamental Data:
| Metric | Value |
|---|---|
| Sector Context | Part of the same broad software pullback affecting HUBS, CRM, NOW, TEAM, TWLO, WDAY |
What Happened: monday.com traded lower in tandem with the broader enterprise software sector pullback today, with no company-specific negative catalyst identified — the decline appears driven entirely by sector rotation.
Why It Matters / What to Watch Tomorrow: As with HubSpot, the lack of a specific negative catalyst suggests this is a broad-based, sentiment-driven pullback rather than a fundamental reassessment. Watch upcoming software-sector earnings for confirmation of whether underlying demand trends remain intact despite today’s price action.
9. Workday (WDAY) — Enterprise Software Rotation Continues
Fundamental Data:
| Metric | Value |
|---|---|
| Sector Context | Declined alongside CRM, HUBS, MNDY, NOW, TEAM, TWLO |
What Happened: Workday shares slipped as part of the same broad-based software sector rotation affecting nearly a dozen previously strong-performing enterprise software names in today’s session.
Why It Matters / What to Watch Tomorrow: With so many software names moving down together on the same day absent individual news, this looks like classic sector-wide profit-taking after a strong run. Watch for whether buyers step back in on any further weakness, which would suggest the pullback is technical rather than fundamental.
10. Twilio (TWLO) — Rounding Out the Software Sector Decline
Fundamental Data:
| Metric | Value |
|---|---|
| Sector Context | Declined alongside CRM, HUBS, MNDY, NOW, TEAM, WDAY, SAP |
What Happened: Twilio shares also participated in today’s broad software sector pullback, with the communications-platform company’s decline driven by the same group-wide rotation rather than any company-specific development.
Why It Matters / What to Watch Tomorrow: As the final name in today’s software-sector pullback group, Twilio’s decline underscores how synchronized the rotation was across the enterprise software space. Watch for Twilio’s next earnings report as the clearest signal of whether underlying business fundamentals justify a resumption of the group’s recent strength.
Quick-Reference Table: Today’s Top 10 Losers
| Rank | Ticker | Company | Today’s Move | Catalyst |
|---|---|---|---|---|
| 1 | NCMI | National CineMedia | -31% | Q2 EPS/revenue miss (despite M&A news) |
| 2 | NBIX | Neurocrine Biosciences | -2% to -5.8% | Vykat XR drug safety concerns |
| 3 | OKLO | Oklo Inc | -4.00% | “Sell the news” despite criticality milestone |
| 4 | PFGC | Performance Food Group | -5% | Q4 and forward guidance miss |
| 5 | NVO | Novo Nordisk | -3.4% | Berenberg downgrade, Lilly competition |
| 6 | TTD | The Trade Desk | -0.52% | Continued weakness near 5-year lows |
| 7 | HUBS | HubSpot | Declined | Sector-wide software pullback |
| 8 | MNDY | monday.com | Declined | Sector-wide software pullback |
| 9 | WDAY | Workday | Declined | Sector-wide software pullback |
| 10 | TWLO | Twilio | Declined | Sector-wide software pullback |
Sector Sentiment Snapshot and Forecast
Today’s losers fall into three distinct categories: earnings and guidance disappointments (National CineMedia, Performance Food Group), binary risk events (Neurocrine’s drug safety concerns, Oklo’s counterintuitive “good news, bad reaction” move), and a broad, seemingly indiscriminate software sector rotation that swept up HubSpot, monday.com, Workday, and Twilio simultaneously. The software pullback is worth watching most closely tomorrow — when nearly a dozen well-known names decline together without individual negative catalysts, it typically reflects profit-taking after a strong run rather than a fundamental shift, and such rotations often reverse quickly once selling pressure exhausts itself. Neurocrine’s drug safety story carries the most serious follow-through risk given the regulatory and reputational stakes involved.
Follow TNN for daily stock market news and financial news today.
Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss. Prices and figures cited reflect data available as of August 12, 2026 and are sourced from publicly available market data. Always complete independent due diligence prior to executing equity trades.
About The Author
